Alnylam Pharmaceuticals stock

ALNY · NASDAQ · USD

Compare Alnylam Pharmaceuticals
$165.04Change from previous close: +5.36%Absolute change: +$8.39

Close · November 13, 2026

Price history

−63.65% over the period

1 year: from $453.97 (November 13, 2025) to $165.04 (November 13, 2026), −63.65%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$165.04
October 30, 2026$165.00
September 30, 2026$246.74
August 31, 2026$240.69
July 31, 2026$205.52
June 30, 2026$301.03
May 29, 2026$301.98
April 30, 2026$309.49
March 31, 2026$330.87
February 27, 2026$332.92
January 30, 2026$338.06
December 31, 2025$397.65
November 28, 2025$451.23
November 13, 2025$453.97

At a glance

  • The company

    Discovers, develops, manufactures and commercializes RNA interference-based therapeutics for rare and common diseases

  • Latest results

    Quarter to September 30, 2026 · EPS $16.26 (estimate $1.74)

TickerLandia's take on Alnylam Pharmaceuticals

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$149.18
52-wk high$479.79

−65.60% from the 52-week high

Analysts · 30 analysts

Average target$299.96+81.75% vs. price

Buy 21 · Hold 9 · Sell 0 · Buy

TickerLandia Fingerprint: Alnylam Pharmaceuticals

Compared with similar companies: very weak momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Alnylam Pharmaceuticals is cheaper than similar companies

Alnylam Pharmaceuticals's P/E (trailing 12 months): 8.34, −75% against the median of a group of 6 similar companies (33.0).

Compared with 6 similar companies

Alnylam Pharmaceuticals's metrics compared with similar companies
MetricAlnylam PharmaceuticalsPosition in the groupBand
P/E (trailing 12 months)8.34Low
Forward P/E15.2Middle
Operating margin19.5%Middle
ROE138.1%High
Debt/equity0.83Middle

Grey band: the middle half of the group; tick: the median; dot: Alnylam Pharmaceuticals. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.29B

Latest quarter · Q2 2026

Net income

$164.49M

Latest quarter · Q2 2026

Quarterly net margin

12.7%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$22.11B
P/E
8.3
EPS
$19.80
Volume
3.59M
Daily trading
€520.28M
Dividend yield
0.00%

How Alnylam Pharmaceuticals is changing

All results
  • Revenue grew 49.8% a year on average over the last 5 years

  • Operating margin rose from −75.7% to 13.5%

  • Shares outstanding up 17.1% in 5 years

Returns

Alnylam Pharmaceuticals returns

$1,000 invested in Alnylam Pharmaceuticals 5 years ago, on November 15, 2021, would be worth $952 today: −4.77% in total, −0.97% per year. This is the price return only: dividends are excluded.

PeriodAlnylam PharmaceuticalsNasdaq 100$1,000 becomes
1 month−26.26%−8.59%$737
6 months−43.38%−4.85%$566
Year to date−58.50%+10.67%$415
1 year−63.65%+11.80%$364
3 years+0.02%+80.48%$1,000
5 years−4.77%+72.61%$952
10 years+229.82%+494.29%$3,298

Over the last 6 months it has done better than 2% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Alnylam Pharmaceuticals: technical analysis

Alnylam Pharmaceuticals is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 66.4% below its all-time closing high ($491.22, October 20, 2025).

Trend
Downward
RSI (14 sessions)
35
Between 30 and 70
vs 200-session average
−40.09%

Support and resistance

Price areas where Alnylam Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$284.69+72.50%4 touches, last on June 3, 2026
  2. Resistance$272.59+65.17%2 touches, last on September 8, 2026
  3. Resistance$235.46+42.67%4 touches, last on October 28, 2026
  4. Last price$165.04
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved little with the Nasdaq 100.

Beta (1 year) vs Nasdaq 100
0.18
Volatility (60 sessions, annualised)
73.4%
Largest fall in the last year
−67.96%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Alnylam Pharmaceuticals: seasonality

Average monthly price change over 23 years

+2.9%Jan+0.3%Feb−1.3%Mar−2.2%Apr+3.8%May+6.1%Jun+8.9%Jul+4.3%Aug+3.4%Sep−5.5%Oct+7.8%Nov+0.6%Dec

Over the last 23 years, the strongest month for Alnylam Pharmaceuticals has been July: +8.86% on average, positive in 15 years out of 23. The weakest has been October: −5.46% on average, positive in 9 years out of 23. November, the current month, has been positive in 16 years out of 22 (+7.84% on average).

Show chart data
MonthAverageMedianPositive years
January+2.88%+0.29%11 of 22
February+0.27%−1.55%10 of 22
March−1.27%−0.69%10 of 22
April−2.19%−1.14%8 of 22
May+3.82%+2.38%13 of 22
June+6.14%+2.66%14 of 23
July+8.86%+3.74%15 of 23
August+4.28%+2.60%14 of 23
September+3.42%+2.13%13 of 23
October−5.46%−8.10%9 of 23
November+7.84%+6.33%16 of 22
December+0.62%−1.00%10 of 22

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Alnylam Pharmaceuticals and its competitors

Alnylam's customers are patients with rare and chronic diseases in the United States, Europe and other international markets, where its RNA interference therapies are sold for conditions such as transthyretin amyloidosis, hypercholesterolemia, hemophilia and primary hyperoxaluria type 1. Its marketed medicines include ONPATTRO, AMVUTTRA, Leqvio, Qfitlia, GIVLAARI and OXLUMO, while its pipeline spans cardiovascular, metabolic, liver, neurological and hematological diseases, with several candidates in Phase 3 trials.

Headquarters
Cambridge, United States
Employees
2,500
Founded
2002
Chief executive
Yvonne Greenstreet
Alnylam Pharmaceuticals and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Alnylam PharmaceuticalsALNY$22.11B19.5%8.34−43.38%
BioNTechBNTX$21.22B-55.4%—−7.19%
IncyteINCY$24.66B32.2%61.7+22.41%
InsmedINSM$26.58B-41.7%—+2.69%
Ascendis PharmaASND$18.06B30.9%18.1+13.06%
Roivant SciencesROIV$28.64B-3,226.3%—+35.28%

Same industry or related industries, similar size. Compare Alnylam Pharmaceuticals with its competitors · Full profile